EA
IMVT icon

Emerald Advisers’s Immunovant IMVT Stock Holding History

Emerald Advisers’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,246
Closed -$158K – 256
2025
Q1 		$158K Sell
9,246
-235,312
-96% -$4.92M 0.01% 213
2024
Q4 		$6.06M Sell
244,558
-5,481
-2% -$155K 0.23% 108
2024
Q3 		$7.13M Sell
250,039
-38,525
-13% -$1.14M 0.28% 105
2024
Q2 		$7.62M Sell
288,564
-14,225
-5% -$405K 0.32% 100
2024
Q1 		$9.78M Sell
302,789
-3,476
-1% -$127K 0.39% 95
2023
Q4 		$12.9M Buy
+306,265
New +$11.3M 0.55% 73
2021
Q1 		– Sell
-603,670
Closed -$27.9M – 276
2020
Q4 		$27.9M Buy
603,670
+62,606
+12% +$2.89M 0.93% 40
2020
Q3 		$19M Buy
+541,064
New +$16.3M 0.78% 53

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Emerald Advisers's IMVT Position: Q2 2025 in Review

Emerald Advisers sold out of Immunovant (IMVT) in Q2 2025, closing a stake of 9,246 shares — an estimated $158K sold.

Emerald Advisers first reported a position in IMVT in Q3 2020 and held it in 8 quarters. The position peaked at $27.9M in Q4 2020. 168 funds tracked by Wall St. Rank hold IMVT as of Q2 2025.

  • Emerald Advisers reported no remaining Immunovant position as of Q2 2025 after selling out during the quarter.
  • Emerald Advisers sold 9,246 Immunovant shares in Q2 2025, an estimated $158K.
  • Emerald Advisers first reported a position in Immunovant in Q3 2020 and held it in 8 quarters.
  • Emerald Advisers's Immunovant position peaked at $27.9M in Q4 2020.
  • 168 funds tracked by Wall St. Rank held Immunovant as of Q2 2025.

Based on Emerald Advisers's 13F filing for Q2 2025, filed 4 Aug 2025.